The global Intestinal Fistula Treatment Market is is projected to be worth US$26.64 billion. The entire demand for intestinal fistula therapy is expected to reach approximately US$ 46.82 billion by 2033, growing at a compound annual growth rate (CAGR) of 5.8% between 2023 and 2033 due to ongoing advancements in biotechnology and pharmaceuticals.
Over the course of the forecast period, factors including the rising prevalence of Crohn’s disease and ulcerative colitis as well as increased awareness of the condition worldwide are anticipated to fuel the expansion of the intestinal fistula treatment market. In order to cure intestinal fistulas, several major industry players are concentrating on research and development as well as looking into new, promising prospects.
Preview Next-Level Insights Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16376
For example, Eli Lilly and Company employed the medicine mirikizumab in phase 3 clinical trials to assess the medication’s long-term safety and efficacy in children and adolescents with Crohn’s disease or moderate-to-severe ulcerative colitis. It is therefore expected that during the forecast period, this will accelerate market growth.
In addition, the growing need for biologics to treat various ailments has pushed industry participants to diversify their product lines and take their products worldwide. Therefore, growing patient preferences for the prescriptions and an increase in regulatory approvals for the drugs introduced by the major players are also anticipated to fuel market expansion in the near future. The main drivers that are anticipated to boost market expansion are a rise in hospitalization cases for the disease and increased awareness of intestinal fistula treatment. According to a 2020 NCBI article, the incidence of ulcerative colitis is between 9 and 20 cases per 100,000 people year.
Key Takeaways from the Market Study
- Global intestinal fistula treatment market was valued at US$ 25.18 Billion by 2022-end
- From 2018 to 2022, the market demand expanded at a CAGR of 2%
- By drug class, proton-pump inhibitors to yield 45% revenue in the global intestinal fistula treatment market
- By distribution channel, the hospital pharmacies segment dominates the market with a share of 46%
- From 2023 to 2033, intestinal fistula treatment worth is expected to flourish at a CAGR of 8%.
- By 2033, the market value of Intestinal Fistula Treatment is expected to reach US$ 82 Billion
“An upsurge in financial support to researchers for developing new innovative drugs for treatment of intestinal fistula, coupled with increasing prevalence of Crohn’s disease are expected to fuel the Intestinal Fistula Treatment Market in the forthcoming years,” remarks an FMI analyst.
Competitive Landscape
- Livealth BioPharma
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Apsolabs
- AstraZeneca
- Pipelinepharma
- Astellas Pharma Inc.
- Caspian Tamin Pharmaceutical Company
- Eli Lilly
- GlaxoSmithKline
- Bristol-Myers Squibb
- Merck & Co. KGaA
- Moderna Inc.
Recent Developments:
- In May 2021, Bristol Myers Squibb announced that the Food and Drug Administration (FDA) approved Zeposia (ozanimod) for the treatment of moderate to severe active ulcerative colitis in adults
- In September 2019, Janssen Biotech, Inc.’s product, STELARA, was approved for the treatment of moderate to severe active ulcerative colitis in the European Union
- In April 2019, Salix Pharmaceuticals entered into an exclusive license agreement with Mitsubishi Tanabe Pharma to commercialize and develop late stage investigational S1P modulator for the treatment of inflammatory bowel disease
- In October 2018, Allergan launched a personalized study approach for clinical research programs in inflammatory bowel disease. These programs would evaluate the efficacy and safety of brazikumab and the potential correlation between biomarkers and the patient outcomes with brazikumab.
Learn About Our Methodological Strategies:
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16376
Key Segments Covered in the Intestinal Fistula Treatment Industry Analysis
By Drug Class:
- Anticholinergic
- Proton-Pump Inhibitors
- H2 Blockers
- Antidiarrheals
By Route of Administration:
- Oral
- Parenteral
- Rectal
- Transdermal
- Intravenous
By Distribution Channel:
- Hospital Pharmacies
- Clinical Pharmacies
- Drug Stores
- Online Pharmacies
Obtain Detailed Market Analysis: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16376
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
